Genetic manipulation of the mammary gland and potential applications
Genetic manipulation of the mammary gland and potential applications |
|
https://doi.org/10.18632/oncotarget.27044
Hiroaki Tagaya,
Kentaro Semba,
and Kosuke Ishikawa
|
| 4253-4254 |
Modified Simon’s minimax and optimal two-stage designs for single-arm phase II cancer clinical trials
Modified Simon’s minimax and optimal two-stage designs for single-arm phase II cancer clinical trials |
|
https://doi.org/10.18632/oncotarget.26981
Jongphil Kim,
and Michael J. Schell
|
| 4255-4261 |
PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix |
|
https://doi.org/10.18632/oncotarget.27008
Minakshi Mann,
Sachin Kumar,
Shyam S. Chauhan,
Neerja Bhatla,
Sunesh Kumar,
Sameer Bakhshi,
Ritu Gupta,
Ashok Sharma,
and Lalit Kumar
|
| 4262-4275 |
AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting
AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting |
|
https://doi.org/10.18632/oncotarget.26945
Alvin Y. Liu,
Adelle D. Kanan,
Tomasz P. Radon,
Siama Shah,
Mark E. Weeks,
Julie M. Foster,
Jane K. Sosabowski,
Laurent Dumartin,
and Tatjana Crnogorac-Jurcevic
|
| 4276-4289 |
Comparative RNA-seq analysis reveals dys-regulation of major canonical pathways in ERG-inducible LNCaP cell progression model of prostate cancer
Comparative RNA-seq analysis reveals dys-regulation of major canonical pathways in ERG-inducible LNCaP cell progression model of prostate cancer |
|
https://doi.org/10.18632/oncotarget.27019
Parameet Kumar,
Joyeeta Chakraborty,
Gauthaman Sukumar,
Clifton Dalgard,
Raghunath Chatterjee,
and Roopa Biswas
|
| 4290-4306 |
CEMIP upregulates BiP to promote breast cancer cell survival in hypoxia
CEMIP upregulates BiP to promote breast cancer cell survival in hypoxia |
|
https://doi.org/10.18632/oncotarget.27036
Anna Banach,
Ya-Ping Jiang,
Eric Roth,
Cem Kuscu,
Jian Cao,
and Richard Z. Lin
|
| 4307-4320 |
Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval
Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval |
|
https://doi.org/10.18632/oncotarget.27039
Eva Ciruelos,
Emilio Alba,
Rafael López,
Anna Lluch,
Miguel Martín,
Isabel Arroyo,
Beatriz Navarro,
David Carcedo,
Ramón Colomer,
and Joan Albanell
|
| 4321-4332 |
The emerging role of human cytomegalovirus infection in human carcinogenesis: a review of current evidence and potential therapeutic implications
The emerging role of human cytomegalovirus infection in human carcinogenesis: a review of current evidence and potential therapeutic implications |
|
https://doi.org/10.18632/oncotarget.27016
Cecilia Söderberg Nauclér,
Jürgen Geisler,
and Katja Vetvik
|
| 4333-4347 |
Correction: Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB
Correction: Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB |
|
https://doi.org/10.18632/oncotarget.27046
Sang Eun Park,
Hye Jin Yi,
Nayoung Suh,
Yun-Yong Park,
Jae-Young Koh,
Seong-Yun Jeong,
Dong-Hyung Cho,
Choung-Soo Kim,
and Jung Jin Hwang
|
| 4348-4349 |
Correction: Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes
Correction: Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes |
|
https://doi.org/10.18632/oncotarget.27048
Garima Yagnik,
Martin Rutkowski,
Sumedh S. Shah,
and Manish K. Aghi
|
| 4350-4350 |
